Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 10/20 | 0.51 |
| ▸ | HTR2A | P28223 | 4/20 | 0.51 |
| ▸ | HTR2C | P28335 | 3/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.51 |
| ▸ | DRD1 | P21728 | 8/20 | 0.49 |
| ▸ | DRD5 | P21918 | 8/20 | 0.49 |
| ▸ | DRD3 | P35462 | 7/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | CA5A | P35218 | 1/20 | 0.48 |
| ▸ | DRD4 | P21917 | 5/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.41 |
| ▸ | PPARA | Q07869 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13005005 | 0.88 | HTR2A (0.63) | DRD2HTR2AHTR2CKCNH2DRD1 | |
| SCHEMBL28524517 | 0.82 | HTR2C (0.52) | DRD2HTR2AHTR2CKCNH2CA2 | |
| SCHEMBL13005014 | 0.79 | DRD2 (0.46) | DRD2HTR2AHTR2CDRD1DRD5 | |
| SCHEMBL4972696 | 0.78 | CA2 (0.49) | HTR2CCA2CA5APPARASIGMAR1 | |
| SCHEMBL31260287 | 0.78 | CA2 (0.49) | HTR2CCA2CA5APPARASIGMAR1 | |
| SCHEMBL13068758 | 0.77 | HTR2A (0.57) | DRD2HTR2AHTR2CKCNH2HRH3 | |
| SCHEMBL13005017 | 0.77 | KMT2A (0.42) | DRD2HTR2AHTR2CKCNH2DRD1 | |
| SCHEMBL4273605 | 0.77 | CYP19A1 (0.59) | HTR2CCA2KMT2A | |
| SCHEMBL5317315 | 0.74 | HTR2A (0.64) | DRD2HTR2AHTR2CKCNH2DRD1 | |
| SCHEMBL521243 | 0.74 | HTR2A (0.42) | DRD2HTR2AHTR2CKCNH2HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100317679-A1 | SUBSTITUTED ARYL-FUSED SPIROCYCLIC AMINES | LIGAND PHARMACEUTICALS, INC. (US) | 2010-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317679-A1 | SUBSTITUTED ARYL-FUSED SPIROCYCLIC AMINES | HRH3, HRH4, HRH2 | DRD2 807/4885HTR2A 203/4885HTR2C 154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.